E-News - May 2023
Alliance Group Chair Election

Dr. Evanthia Galanis Elected Alliance Group Chair-Elect

The Alliance Board of Directors has elected Evanthia Galanis, MD, as Group Chair-Elect of the Alliance for Clinical Trials in Oncology at the 2023 Alliance Spring Virtual Group Meeting on May 5. Dr. Galanis will take office in November 2023 and will serve a six-year term.

“I’m honored to be elected to serve as Group Chair of the Alliance,” Dr. Galanis said. “I am excited to lead an organization whose mission is to reduce the impact of cancer by uniting a broad community of scientists and clinicians who are committed to the prevention and treatment of cancer. I am also inspired by the Alliance’s unique potential and look forward to leveraging our many strengths to fulfill our mission, expand and grow our research initiatives, address cancer health disparities in our communities and partner with NCI to end the burden of cancer as we know it.”

Dr. Galanis is the Sandra J. Schulze Professor of Novel Therapeutics, Professor of Oncology, and has joint appointments in the Division of Medical Oncology - Department of Oncology, and the Department of Molecular Medicine at the Mayo Clinic. She is Co-Chair of the NCI’s Glioblastoma/Brain Metastases Interest  Group and has served as the U.S. lead for the international rare brain tumor initiative. She also serves as Chair of the Alliance Neuro-Oncology Committee and has been a member of the Alliance since 2011. Prior to that, she served as Co-Chair (2009-2011) and Vice-Chair (2002-2008) of the North Central Caner Treatment Group’s Neuro-Oncology Committee.

Dr. Galanis received her M.D. from Athens University School of Medicine and completed her residency in internal medicine and her fellowship in Hematology/Oncology at the Mayo Graduate School of Medicine. Subsequently, she joined the faculty at Mayo Clinic.

As Group Chair-Elect, Dr. Galanis will succeed Interim Group Chair Suzanne George, MD, who assumed the role after Monica M. Bertagnolli, MD, was appointed to serve as the Director of the National Cancer Institute in 2022.